In:
Science Immunology, American Association for the Advancement of Science (AAAS), Vol. 8, No. 79 ( 2023-01-27)
Abstract:
Agents that activate the DNA-sensing cGAS-STING pathway have been explored for cancer immunotherapy in both preclinical and clinical settings, but how to optimally activate the pathway remains unclear. Jneid et al . found that incorporation of the naturally occurring STING ligand cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) into non-infectious enveloped virus-like particles (VLPs) selectively activates STING in antigen-presenting cells (APCs) including dendritic cells when administered intratumorally. Compared to a non-targeted synthetic STING agonist, VLPs delivering cGAMP systemically enhanced tumor-specific T cell responses and anti-tumor effects during immune checkpoint blockade in mice. These results demonstrate that selectively targeting STING agonists to APCs may improve their therapeutic effects, particularly in poorly immunogenic tumors. —CO
Type of Medium:
Online Resource
ISSN:
2470-9468
DOI:
10.1126/sciimmunol.abn6612
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
Permalink